Does left bundle branch area pacing reduce adverse clinical outcomes and improve cardiac remodeling compared to biventricular pacing in patients undergoing cardiac resynchronization therapy?
LBBAP is associated with significantly lower risks of mortality and heart failure hospitalization, as well as greater improvements in LVEF, compared to traditional biventricular pacing for CRT.
Background: Biventricular pacing (BiVP) is the conventional approach for cardiac resynchronization therapy (CRT), yet approximately one-third of patients show no clinical response. Left bundle branch area pacing (LBBAP) enables more physiological ventricular activation through His-Purkinje conduction, but its impact on key clinical endpoints such as all-cause mortality and heart failure hospitalization (HFH) remains debated. Methods: A systematic search of PubMed, Embase, Cochrane Library, and CNKI (to May 3, 2025) identified 24 studies encompassing 6, 538 patients. Study quality was assessed using Cochrane RoB 2. 0 and the Newcastle-Ottawa Scale. Subgroup analyses (by follow-up duration, study design, and sex), leave-one-out sensitivity analysis, and meta-regression were performed to assess result robustness and heterogeneity sources. Trim-and-fill correction was applied to adjust for potential publication bias. Results: LBBAP was associated with a markedly lower risk compared to BiVP across several clinical outcomes. Specifically, it significantly reduced the risk of the composite endpoint (HR: 0. 67, 95% CI: 0. 59-0. 75), all-cause mortality (HR: 0. 83, 95% CI: 0. 71-0. 96), and HFH (HR: 0. 58, 95% CI: 0. 50-0. 67). Echocardiographic outcomes further supported LBBAP superiority, with higher rates of echocardiographic response (OR: 1. 57, 95% CI: 1. 36-1. 81) and super-response (OR: 2. 12, 95% CI: 1. 62-2. 76). Improvements in left ventricular ejection fraction (LVEF) were greater with LBBAP at both 3-6 months (MD: 5. 31%, 95% CI: 4. 63-5. 99) and ≥12 months (MD: 4. 43%, 95% CI: 2. 27-6. 60). Similarly, left ventricular end-diastolic diameter (LVEDD) reductions were more pronounced at 3-6 months (MD: -3. 48 mm, 95% CI: -5. 76 to -1. 21) and ≥12 months (MD: -2. 86 mm, 95% CI: -5. 05 to -0. 68). Conclusions: These findings indicate that LBBAP provides superior clinical and structural outcomes compared to BiVP in patients undergoing CRT. Large-scale, multicenter randomized controlled trials are warranted to confirm these results, assess long-term efficacy, and elucidate gender-specific variations to optimize evidence-based CRT delivery. Systematic Review Registration: https: //www. crd. york. ac. uk/prospero/displayᵣecord. php? ID=CRD420251055488, PROSPERO CRD420251055488.
Zheng et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: